The inhaled COVID-19 vaccine developed by China has been promoted as a potential booster against the Omicron variant. However, concerns have been raised about the lack of scientific evidence supporting its efficacy. Dive into the available data and understand the debate surrounding this novel vaccination method.
Summary
The inhaled COVID-19 vaccine from China has been promoted as an Omicron booster, but concerns have been raised due to the lack of scientific evidence supporting its efficacy. With clinical trials not sufficiently demonstrating its effectiveness against the Omicron variant, the debate surrounding this novel vaccination method continues.
Comments
0